#antiviral

The antiviral treatment is safe and effective for pediatric patients ages 12 and up.

People with HIV are at greater risk for hepatitis B but are less likely to get vaccinated and respond to vaccines.

The new drug reduced HDV viral load and lowered liver enzyme levels in people with hepatitis B and D.

Paxlovid and molnupiravir can reduce the risk of severe COVID-19, but they must be started within five days of symptom onset.

Molnupiravir is authorized for people at high risk for severe COVID-19 when other treatment options are not available.

Paxlovid, which reduces the risk of hospitalization or death by about 90%, is expected to be a game-changer.

The new drugs must be used within a narrow window of time after developing symptoms.

Molnupiravir reduces severe illness and death, but it must be started within days after developing symptoms.

Post-exposure and pre-exposure prophylaxis could be a game-changer for immunocompromised people.

People under 50 who were cured of hepatitis C were at comparable risk to the general population.

The government-wide effort aims to develop the next generation of COVID-19 treatments to prepare the U.S. to respond to future virus threats

Positive diagnostic tests and drug prescriptions dropped 40% in July 2020 compared with earlier years.

Suppression of hepatitis B virus with antiviral treatment lowered the risk of hepatocellular carcinoma by 58%.

Assessing patient-reported outcomes can support treatment for hard-to-reach populations.

People who received treatment had a lower composite risk of cirrhosis, liver cancer and death.

The risk was lower in people who had achieved a sustained virological response compared with those who had not.